Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

While pivotal trial data for liso-cel showed a modest 20% complete response rate, real-world studies demonstrate complete response rates reaching 40% to 50%. Dr. Koons notes that heavily pretreated patients lacking effective bridging agents often presented with bulky disease, which pirtobrutinib bridging helps control prior to CAR-T.

Related Insights

To maximize the effectiveness of CD19-directed CAR-T therapy (Lysocel) in CLL, patients should be referred while still responding to their latest line of salvage therapy, such as pirtobrutinib. This approach leverages less-exhausted T-cells and real-world data shows it leads to higher complete remission rates.

Experts now view a patient's response to bridging therapy as a key predictor of CAR T outcomes. A patient who fails to respond or progresses during bridging has a much higher risk of toxicity and poor efficacy and should be considered for alternative treatments.

BTK inhibitors like ibrutinib can improve T-cell function. When combined with liso-cel CAR-T, this synergistic effect dramatically improves outcomes in heavily pretreated patients, increasing the complete response rate from 20% to 45% and the overall response rate from 48% to 86%.

It's a myth that patients must have active disease to receive their manufactured CAR-T cells. Data from the TRANSFORM study shows that patients who achieved a complete response with bridging therapy while awaiting cell manufacturing still proceeded with the infusion and benefited.

Despite strong single-agent trial results, experts believe the field is shifting away from continuous monotherapy. The most significant future impact for pirtobrutinib will likely be as a backbone of fixed-duration combination therapies with drugs like venetoclax, aiming for deeper remissions without indefinite treatment.

Data from the BRUIN CLL-322 trial shows that adding pirtobrutinib to venetoclax-rituximab (PVR) significantly improves progression-free survival for CLL patients who have previously been treated with a BTK inhibitor. This establishes the triplet as a new, potent, and likely future standard regimen for this high-need population.

Abstract data from the BRUIN CLL-322 trial reveals that adding pirtobrutinib to a venetoclax-rituximab backbone provides a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients with previously treated CLL, without a substantial increase in toxicity.

Contrary to typical findings where real-world data underperforms, liso-cel CAR T-cell therapy in CLL demonstrates significantly better outcomes in practice than in its approval trial (over 80% response rate vs. under 50%). This suggests that using the therapy earlier in healthier, less-refractory patients unlocks its true potential.

For high-risk CLL patients who progress after both covalent BTK inhibitors and venetoclax, pirtobrutinib is not just the next line of therapy. It is strategically used to achieve disease control, creating a window to prepare the patient for a more definitive and potentially curative CAR-T cell therapy.

Current CAR-T therapy for CLL requires a complete response (CR) for long-term benefit. A partial response provides only about two years of disease control, an outcome similar to the oral drug pirtobrutinib but with significantly more toxicity, complexity, and logistical burden for the patient.